Human TRBC2 Protein, His Tag, low endotoxin (MALS verified)

Cat. No. / Size
Price
Availability
Qty
TR2-H52H3-100ug
$360.00
In Stock - Delivery in 1-2 business days
TR2-H52H3-1mg
$2,380.00
TR2-H52H3
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

T cell receptor beta constant 2, TRBC2

Source

Human TRBC2, His Tag (TR2-H52H3) is expressed from human 293 cells (HEK293). It contains AA Asp 1 - Ala 144 (Accession # A0A5B9-1).

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 18.3 kDa. The protein migrates as 19-21 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

The transmembrane protein, TCR, comprise of two disulphide-linked polypeptide chains: a α and β chain, a γ and δ chain. Each polypeptide chain consists of a variable and a constant region. TRBC2 is the constant region of T-cell receptor (TCR) beta chain. TRBC2 is presented on the surface of T cell and recognized peptide-major histocompatibility (MH) (pMH) that are displayed by antigen presenting cells (APC). TRBC2 is participate in an adaptive immune response and has been well-studied in T cell therapy.